Primary outcomes of the placebo-controlled phase 2 study PERSEUS (NCT01360840) investigating two dose regimens of abituzumab (DI17E6, EMD 525797) in the treatment of chemotherapy-naive patients (pts) with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Authors

Maha Hussain

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Maha Hussain , Kurt Miller , Ilona Rybicka , Rolf Bruns

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In